Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

3D model helps surgeons target cancer spread in prostate patients

NCT ID NCT07129551

Knowledge-focused Sponsor: Martini-Klinik am UKE GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a 3D virtual model, created from PSMA PET scans, can help surgeons better remove lymph node metastases in prostate cancer patients. About 102 participants will undergo surgery with the model used for planning and guidance. Researchers will measure how many metastases are removed, surgical precision, and patient quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
virtual 3D model
What this could lead to
If successful, this could improve how surgeons find and remove lymph node metastases, potentially leading to better cancer control and quality of life for prostate cancer patients.
What could go wrong
This is a small feasibility study (102 participants) without a control group, so results may not be generalizable. The 3D model is a navigation aid, not a new treatment, and may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 102 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 78 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Cohort A: * Patients with hormone-sensitive prostate cancer scheduled for radical prostatectomy with pelvic lymph node dissection * \<3 PSMA-PET-avid lymph node metastases (PSMA expression score \>2) in the pelvis. Cohort B: * Patients with hormone-sensitive recurrent prostate cancer after radical prostatectomy with planned pelvic salvage lymph node dissection * \<3 PSMA-PET-avid lymph node metastases (PSMA expression score \>2) in the pelvis * PSA value \<2ng/ml. Exclusion Criteria: * Estimated life expectancy \<10 years * contraindication for surgical intervention * androgen deprivation therapy (ADT) within the last 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer (adenocarcinoma) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer (adenocarcinoma)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Anke Renter

    NOT_YET_RECRUITING

    Hamburg, Free and Hanseatic City of Hamburg, 25479, Germany

  • Martini-Klinik

    RECRUITING

    Hamburg, Free and Hanseatic City of Hamburg, 20246, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.